Age-related efficacy and safety of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in subgroups of patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Post hoc analysis of SPARTAN.
暂无分享,去创建一个
F. Saad | B. Hadaschik | E. Small | P. Mainwaring | S. Oudard | J. Lee | D. Olmos | Matthew R. Smith | H. Uemura | A. Londhe | A. Bhaumik | J. Graff | A. Lopez‐Gitlitz | Oliver Brendan Rooney